STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

KPTI Schedule 13G filing by T. Rowe Price Investment Management

T. Rowe Price Investment Management reported beneficial ownership of 728.8K shares, representing 12% of KARYOPHARM THERAPEUTICS INC in this filing.

FiledAug 14, 2025
Ownership dateJun 30, 2025
Reported shares728.8K
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 728.8K
Shared voting power 728.8K
Sole dispositive power 728.8K
Shared dispositive power 728.8K
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$4.65as of Aug 14, 2025
Latest tracked price$1.99as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
T. Rowe Price Investment Management
CIK
CIK0001897612
Accession
0001897612-25-000365
Form
Schedule 13G
Open SEC filing View KPTI ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →